Cost‐effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China

• Główni autorzy: Hongtao Wei (Autor), Can Cui (Autor), Xiangli Cui (Autor), Yi Liu (Autor), Dandan Li (Autor)
• Format: Książka
• Wydane: BMC, 2021-01-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

Abstract Background and objective To evaluate the cost-effectiveness of new anticoagulants and warfarin in the prevention of stroke in Chinese patients with atrial fibrillation (AF). Methods The Markov model was constructed to compare patients' quality-adjusted life-years (QALYs) using drug cos...